Biomarkers for cystic fibrosis lung disease: Application of SELDI-TOF mass spectrometry to BAL fluid Gordon MacGregor, Robert D. Gray, Thomas N. Hilliard,

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations

Adiponectin and body composition in cystic fibrosis

Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus Magnus Hillman, Leif Eriksson, Lena Mared, Karin Helgesson,

Neil E. Alexis, Marianne S. Muhlebach, David B. Peden, Terry L. Noah

TLR4, ATF-3 and IL8 inflammation mediator expression correlates with seizure frequency in human epileptic brain tissue Katharina Pernhorst, Stefan Herms,

Megan W. France, Mary E. Dodd, John R. Govan, Catherine J. Doherty, A

Development, validation, and implementation of a questionnaire assessing disease knowledge and understanding in adult cystic fibrosis patients Karen.

Platelet proinflammatory activity in clinically stable patients with CF starts in early childhood Alexander Sturm, Helge Hebestreit, Corinne Koenig,

Use of high-dose ibuprofen in a pediatric cystic fibrosis center

R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J

Cortical stimulation parameters for functional mapping

Abaigeal D. Jackson, Christopher H. Goss Journal of Cystic Fibrosis

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H

Melissa S. Putman, Joshua F

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

500 years later: Understanding the genetic ancestry of the southeast region, brazil D.F. Braganholi, I.B. Ambrosio, F.S. Polverari, J. Martinez, R.M.B.

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

S. Dangsriwan, P. Thanakiatkrai, W. Asawutmangkul, S. Phetpeng, T

Pulmonary exacerbations in CF patients with early lung disease

Controlled clinical trials in cystic fibrosis — are we doing better?

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Advanced glycation end products are elevated in cystic fibrosis-related diabetes and correlate with worse lung function William R. Hunt, Beth R. Helfman,

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Controversies with Kalydeco: Newspaper coverage in Canada and the United States of the cystic fibrosis “wonder drug” Christen Rachul, Maeghan Toews,

The Journal of Cystic Fibrosis: Sunny perspectives

Vitamin A and lung function in CF

P. aeruginosa in the paranasal sinuses and transplanted lungs have similar adaptive mutations as isolates from chronically infected CF lungs Oana Ciofu,

Rajeev Soni, Catherine J. Dobbin, Maree A. Milross, Iven H

A.H. Gifford Journal of Cystic Fibrosis

Oxidized glutathione and uric acid as biomarkers of early cystic fibrosis lung disease Nina Dickerhof, Rufus Turner, Irada Khalilova, Emmanuelle Fantino,

M. Al-Aloul, M. Jackson, G. Bell, M. Ledson, M. Walshaw

Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C

Characterisation of mutations and genotype–phenotype correlation in cystic fibrosis: Experience from India Shivaram S. Shastri, Madhulika Kabra, Sushil.

Christiane I. -U. Chen, Susanne Schaller-Bals, Karl P

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Anastasios Lekkas, Khin M. Gyi, Margaret E. Hodson

Cytokine gene polymorphisms and severity of CF lung disease

Nasal polyposis in lung transplant recipients with cystic fibrosis

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention H. White, K. Pollard, C. Etherington, I. Clifton,

Disease disclosure in individuals with cystic fibrosis: Association with psychosocial and health outcomes Adrienne P. Borschuk, Robin S. Everhart, Michelle.

Lung clearance index during hospital admission in school-age children with cystic fibrosis Liam Welsh, Christopher Nesci, Haily Tran, Marisol Tomai,

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

Diabetes mellitus and survival in cystic fibrosis patients after lung transplantation Markus Hofer, Christoph Schmid, Christian Benden, Rudolf Speich,

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

Colombian results of the interlaboratory quality control exercise 2015

Voriconazole therapy in children with cystic fibrosis

CFTR modulators and pregnancy: Our work has only just begun

N Dauletbaev, K Viel, R Buhl, T.O.F Wagner, J Bargon

Brian S. Murphy, Heather M

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Absence of a gender gap in survival

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Uta Griesenbach, A. Christopher Boyd Journal of Cystic Fibrosis

H. White, A.M. Morton, D.G. Peckham, S.P. Conway

Presentation transcript:

Biomarkers for cystic fibrosis lung disease: Application of SELDI-TOF mass spectrometry to BAL fluid Gordon MacGregor, Robert D. Gray, Thomas N. Hilliard, Margaret Imrie, A. Christopher Boyd, Eric W.F.W. Alton, Andrew Bush, Jane C. Davies, J. Alastair Innes, David J. Porteous, Andrew P. Greening Journal of Cystic Fibrosis Volume 7, Issue 5, Pages 352-358 (September 2008) DOI: 10.1016/j.jcf.2007.12.005 Copyright © 2008 Terms and Conditions

Fig. 1 Heat Map of protein expression on IMAC Ni surface. Areas of red represent overexpressed proteins. Hierarchical clustering separates most CF subjects from control subjects. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Journal of Cystic Fibrosis 2008 7, 352-358DOI: (10.1016/j.jcf.2007.12.005) Copyright © 2008 Terms and Conditions

Fig. 2 The relative intensities of protein marker 5.163 kDa for CF patients and control subjects are shown. Complete separation of the two groups is seen (p<0.001). The data are from the IMAC Nickel surface. Journal of Cystic Fibrosis 2008 7, 352-358DOI: (10.1016/j.jcf.2007.12.005) Copyright © 2008 Terms and Conditions

Fig. 3 The relative intensities of s100 A8 (calgranulin A), on the IMAC nickel surface, for CF patients, disease controls excluding primary ciliary dyskinesia (PCD) patients, and primary ciliary dyskinesia patients. S100A8 was significantly raised in CF compared with PCD (p<0.05) and with disease controls excluding PCD (p<0.01). Journal of Cystic Fibrosis 2008 7, 352-358DOI: (10.1016/j.jcf.2007.12.005) Copyright © 2008 Terms and Conditions

Fig. 4 Correlations of s100 A8 (panel A; p=0.0025) and s100 A12 (panel B; p=0.0016) with percent BAL neutrophils, in CF patients. Journal of Cystic Fibrosis 2008 7, 352-358DOI: (10.1016/j.jcf.2007.12.005) Copyright © 2008 Terms and Conditions